Lithium : old & new uses in medicine by Birch, Nicholas J. & Gallicchio, Vincent S.
Maltese Medical Journal 7 Volume VII Issue I 1995 
LITHIUM: OLD & NEW USES IN MEDICINE 
N. J. Birch, V. S. Gallicchio 
1 

I 

1, 
Lithium has been used in psychiatry since 19491: 
since the mid 1960s its use has escalated until it 
is estimated that about 500,000 patients receive it 
wor1d-wide. Despite many scares lithium is a 
very safe drug in experienced hands and it has 
particular importance in the prophylactic 
treatment of the recurrent affective disorders, the 
manic-depressive psychoses, where its ability to 
reduce or abolish the mood swings has 
undoubtedly improved immensely the quality of 
life of many patients and their families and saved 
many lives of those who would otherwise have 
been led to suicide 2.3. 
These psychiatric benefits have been gained from 
a drug which is a simple metal ion whose 
chemistry is apparently simple and whose mode 
of action is unknown. Whatever can be said of 
lithium, it is of fundamental interest for us to 
discover what exactly lithium does at the 
molecular level which makes it so effective in 
psychiatry since this may give us insight into the 
most basic features of the cellular response to 
drugs: lithium does not, after all, have a large 
and convoluted structure which can make 
multiple contacts with receptors which may lead 
to modification of receptor activation. Whatever 
lithium does, it achieves because it is a highly 
charged cation with a large hydrated radius and 
chemical properties which are similar to 
magnesium 4,5. 
During the last decade a new phase of interest in 
lithium has begun with the discovery of effects 
which are unrelated to its psychiatric use. Many 
of these effects are derived from the well 
established modification by lithium of 
haematopoeitic processes notably the stimulation 
by lithium of leucocytosis 6. Initially this effect 
was exploited for the treatment of drug-induced 
haematopoeitic suppression7.8, for example in 
chemotherapy of cancers 9.10. The metal also has 
effects on immunologic responses to a number of 
challenges 11. However, in the process of such 
investigations it has become clear that lithium 
can influence a series of cytokines which regulate 
such cell differentiation not only in blood 
forming cells but also in other cell types. 
Lithium ion selective electrodes are now 
commercially available and represent the most 
effective way of ensuring compliance in lithium 
treated patients 12. Not only are they accurate 
within the clinically useful range but they also 
provide the long-sought opportunity for 
psychiatrists to measure blood lithium in the 
presence of the patient who can thereby be 
challenged about non-compliance or counselled 
and the dose regulated accordingly. It is possible 
to reduce the time required to institute lithium 
therapy because there is no delay in receiving the 
results of preliminary test doses. 
A modified ion-selective electrode technique is 
under clinical testing for the measurement of 
cardiac output in patients with cardiovascular 
disease 13. A disposable lithium electrode is 
placed in the arterial line, usually already in place 
in these patients and a small injection of a lithium 
salt is made into the venous line, the resultant 
lithium signal being integrated on a 
microcomputer connected to the electrode. Such 
a process can replace techniques currently in use 
and which require the insertion of additional 
cannulae into an already seriously ill patient. 
An effect of lithium on virus replication was 
demonstrated in the ear1y 1980s and this has 
formed the basis for the topical treatment of 
Herpes simplex by lithium succinate ointment 14. 
Other dermatological responses soon were seen 
and in Britain, lithium is licenced for the 
treatment of sebolThoeic dermatitis 15. A detailed 
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study of the effects of lithium on essential fatty 
acid metabolism showed that it interfered with 
the fungi of the Pityrosporum sp. which are the 
ultimate cause of the latter disease. In the course 
of related studies it was found that the lithium 
salt of the essential fatty acid, gamma-linoleic­
acid (LiGLA) was cytotoxic to a wide range of 
cancer cells in cultures, apparently because of its 
inhibition of the 6-desaturase enzyme which is 
the rate limiting step on the metabolic pathway of 
both the (n-3) and (n-6) unsaturated fatty 
acids 16.17. Clinical trials are currently under way 
and results are encouraging. Because of the 
effects on cytokine production, lithium ion alone 
has been shown to have direct effects on cancer 
cell proliferation. 
Perhaps the most significant new area of 
influence derives from the inhibition of viral 
replication. It has been shown that lithium 
reverses the development of the disease process 
in murine immunodeficiency disease, the so 
called mouse AIDS (MAIDS) virus 7,18. This 
was discovered because lithium was tested as a 
means of stimulating leucocyte production in 
AIDS patients treated with Zidovudine (AZT) 
whose haematopoeiesis was compromised by the 
administered drug. Lithium not only reversed the 
leucopaenia, but also, in the control groups of 
MAIDS infected animals, lithium had a direct 
effect on the viral replication and reversed the 
lymphoma commonly seen in these animals. 
After lithium, the virus content of tissues 
markedly declined and the lymphoma apparently 
disappeared. Human AIDS infected cell lines 
also appear to be affected in a similar way18 and 
clinical trials in human AIDS patients are now 
under way. 
That all this can be achieved by a metal ion salt 
which can be dug out of the ground in North 
Carolina is, of course, not popular with the 
'Ethical' drug companies and there is little 
funding of such research. It is clear that lithium 
has a future in therapeutics but that in order to 
develop to its full potential it will be necessary to 
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